Performance of the Use of Genetic Information to Assess the Risk of Colorectal Cancer in the Basque Population.
Mendelian randomization
colorectal cancer
genome-wide association study
polygenic risk scores
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Aug 2022
29 Aug 2022
Historique:
received:
16
06
2022
revised:
18
08
2022
accepted:
26
08
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
10
9
2022
Statut:
epublish
Résumé
Although the genetic contribution to colorectal cancer (CRC) has been studied in various populations, studies on the applicability of available genetic information in the Basque population are scarce. In total, 835 CRC cases and 940 controls from the Basque population were genotyped and genome-wide association studies were carried out. Mendelian Randomization analyses were used to discover the effect of modifiable risk factors and microbiota on CRC. In total, 25 polygenic risk score models were evaluated to assess their performance in CRC risk calculation. Moreover, 492 inflammatory bowel disease cases were used to assess whether that genetic information would not confuse both conditions. Five suggestive (p < 5 × 10−6) loci were associated with CRC risk, where genes previously associated with CRC were located (e.g., ABCA12, ATIC or ERBB4). Moreover, the analyses of CRC locations detected additional genes consistent with the biology of CRC. The possible contribution of cholesterol, BMI, Firmicutes and Cyanobacteria to CRC risk was detected by Mendelian Randomization. Finally, although polygenic risk score models showed variable performance, the best model performed correctly regardless of the location and did not misclassify inflammatory bowel disease cases. Our results are consistent with CRC biology and genetic risk models and could be applied to assess CRC risk in the Basque population.
Identifiants
pubmed: 36077729
pii: cancers14174193
doi: 10.3390/cancers14174193
pmc: PMC9454881
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Diputación Foral de Gipuzkoa
Références
J Transl Med. 2019 Oct 29;17(1):353
pubmed: 31665031
Elife. 2018 May 30;7:
pubmed: 29846171
Nat Commun. 2018 Jan 15;9(1):224
pubmed: 29335400
J Cell Physiol. 2020 May;235(5):4824-4833
pubmed: 31709544
Proc Natl Acad Sci U S A. 2015 Sep 22;112(38):11917-22
pubmed: 26351665
Cancer Res. 2010 Mar 15;70(6):2406-14
pubmed: 20215514
Nat Genet. 2021 Apr;53(4):420-425
pubmed: 33692568
Int J Colorectal Dis. 2009 Sep;24(9):1059-68
pubmed: 19390858
PLoS Genet. 2018 Jun 20;14(6):e1007376
pubmed: 29924794
Int J Clin Exp Pathol. 2020 Sep 01;13(9):2280-2288
pubmed: 33042332
Nat Genet. 2021 Feb;53(2):156-165
pubmed: 33462485
J Clin Lab Anal. 2021 Oct;35(10):e23961
pubmed: 34477243
Nat Genet. 2016 Oct;48(10):1279-83
pubmed: 27548312
World J Surg Oncol. 2017 Jun 19;15(1):115
pubmed: 28629469
Int J Cancer. 2017 Jun 15;140(12):2701-2708
pubmed: 28340513
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Gastroenterology. 2009 Jan;136(1):217-26
pubmed: 18973758
Gut. 2021 Jul;70(7):1325-1334
pubmed: 33632709
Front Med (Lausanne). 2021 Dec 06;8:795849
pubmed: 34938753
Cancers (Basel). 2021 Dec 10;13(24):
pubmed: 34944836
Am J Hum Genet. 2020 Nov 5;107(5):815-836
pubmed: 32991828
J Clin Lab Anal. 2020 Oct;34(10):e23431
pubmed: 32533587
Sci Rep. 2017 Feb 24;7:43263
pubmed: 28233817
Tumour Biol. 2017 May;39(5):1010428317699800
pubmed: 28468577
Gigascience. 2015 Feb 25;4:7
pubmed: 25722852
Nat Commun. 2020 Nov 27;11(1):6084
pubmed: 33247094
Bioinformatics. 2017 Sep 01;33(17):2776-2778
pubmed: 28475694
Nat Commun. 2019 May 14;10(1):2154
pubmed: 31089142
Carcinogenesis. 2015 Jul;36(7):710-8
pubmed: 25916654
Gastroenterology. 2015 Jun;148(7):1330-9.e14
pubmed: 25683114
Mutagenesis. 2012 Mar;27(2):187-96
pubmed: 22294766
Bioinformatics. 2014 May 1;30(9):1266-72
pubmed: 24413527
Eur Rev Med Pharmacol Sci. 2020 Oct;24(20):10542-10549
pubmed: 33155210
Cancer Causes Control. 2015 Mar;26(3):467-73
pubmed: 25618792
Sci Rep. 2022 Mar 1;12(1):3386
pubmed: 35232999
Int J Epidemiol. 2011 Jun;40(3):755-64
pubmed: 21414999
Front Cell Dev Biol. 2021 May 24;9:659392
pubmed: 34109174
Nat Rev Gastroenterol Hepatol. 2019 Nov;16(11):690-704
pubmed: 31554963
Mol Med Rep. 2020 Apr;21(4):1779-1788
pubmed: 32319604
Lab Invest. 2010 Oct;90(10):1415-24
pubmed: 20585313
BMC Cancer. 2011 Aug 05;11:339
pubmed: 21819567
JNCI Cancer Spectr. 2020 Mar 12;4(3):pkaa021
pubmed: 32596635
Sci Transl Med. 2014 Mar 19;6(228):228ra37
pubmed: 24648340
Nucleic Acids Res. 2019 Jan 8;47(D1):D1005-D1012
pubmed: 30445434
Cancers (Basel). 2020 May 02;12(5):
pubmed: 32370168
Nat Immunol. 2016 Mar;17(3):230-40
pubmed: 26882261
Nat Commun. 2021 Feb 12;12(1):970
pubmed: 33579919
Nat Genet. 2019 Jan;51(1):76-87
pubmed: 30510241
Sci Rep. 2016 May 19;6:26337
pubmed: 27194068
Gut. 2017 Apr;66(4):633-643
pubmed: 26992426
Cancer Res. 2019 Nov 1;79(21):5575-5586
pubmed: 31506332
Gastroenterology. 2020 Apr;158(5):1274-1286.e12
pubmed: 31866242
Science. 2019 Mar 15;363(6432):1230-1234
pubmed: 30872528
Front Oncol. 2021 Sep 13;11:732743
pubmed: 34589434
Cancer Med. 2019 Jun;8(6):3196-3205
pubmed: 30968590
Anticancer Res. 2013 Jan;33(1):167-73
pubmed: 23267142
Am J Hum Genet. 2020 Sep 3;107(3):432-444
pubmed: 32758450
Mol Aspects Med. 2019 Oct;69:93-106
pubmed: 31082399
Nat Genet. 2016 Nov;48(11):1443-1448
pubmed: 27694958
Lancet Gastroenterol Hepatol. 2020 Jan;5(1):55-62
pubmed: 31668584
BMC Med Genomics. 2020 Jul 29;13(1):108
pubmed: 32727450
Genome Res. 2009 Sep;19(9):1655-64
pubmed: 19648217
J Natl Cancer Inst. 2019 Feb 1;111(2):146-157
pubmed: 29917119
Gastroenterology. 2010 Sep;139(3):788-96, 796.e1-6
pubmed: 20638935
PLoS One. 2013;8(1):e53916
pubmed: 23349764
PLoS One. 2019 Dec 10;14(12):e0225779
pubmed: 31821333
Clin Cancer Res. 2014 Aug 1;20(15):4115-28
pubmed: 24893630
Front Genet. 2021 Sep 13;12:647152
pubmed: 34589110
CA Cancer J Clin. 2008 May-Jun;58(3):130-60
pubmed: 18322143
Eur Surg Res. 2021;62(4):248-254
pubmed: 34198297
Microorganisms. 2021 May 20;9(5):
pubmed: 34065545